Bicycle Therapeutics Limited Stock Price, News & Analysis

Bicycle Therapeutics plc (NASDAQ: BCYC) announced its participation in three virtual investor conferences in June 2021. The events include:

• Jefferies Virtual Healthcare Conference on June 3 at 11:00 a.m. ET
• Goldman Sachs 42nd Annual Global Healthcare Conference on June 8 at 8:00 a.m. ET
• JMP Securities Life Sciences Conference on June 17 at 12:00 p.m. ET

Investors can access live webcasts on the company’s website, with archives available for 30 days post-event. Bicycle focuses on developing its proprietary Bicycle® technology for treating underserved diseases.

Bicycle Therapeutics (NASDAQ: BCYC) announced its financial results for Q1 2021, reporting cash of $195.9 million, an increase from $136.0 million at the end of 2020. The company is advancing its Bicycle Toxin Conjugates and plans to enter the clinic with lead compound BT7480 later this year. Research & development expenses rose to $9.7 million with a net loss of $16.2 million for the quarter. Bicycle continues to strengthen its balance sheet through an ATM offering, raising $75 million since January 2021. The firm is optimistic about its clinical milestones through 2024.

Bicycle Therapeutics (NASDAQ: BCYC) has announced the virtual presentation of preclinical findings on BT7480, an innovative Nectin-4/CD137 tumor-targeted immune cell agonist (TICA^TM), at the AACR Annual Meeting on April 10-15, 2021. The company will also showcase additional data on TICAs and Bicycle Toxin Conjugates (BTCs) through various sessions and e-posters. BT7480 is expected to enter clinical trials in H2 2021, highlighting Bicycle's commitment to advancing its immuno-oncology pipeline.

Bicycle Therapeutics (NASDAQ: BCYC) has announced progress updates on its bicyclic peptide technology and partnered programs beyond oncology. The company has achieved its first milestone in collaboration with the Dementia Discovery Fund, focusing on TREM2 and transferrin receptor 1 targets. Additionally, it received funding to develop antimicrobial agents and COVID-19 solutions. Collaborations with AstraZeneca and Bioverativ continue, with assets being advanced for respiratory diseases and rare hematological conditions. Four Bicycle molecules are now in clinical trials, indicating potential for new treatments.

Bicycle Therapeutics (NASDAQ: BCYC) announces the appointment of Dr. Jose-Carlos Gutierrez-Ramos to its Board of Directors. With extensive experience in biopharmaceuticals, Dr. Gutierrez-Ramos aims to leverage his background in drug development to enhance Bicycle’s clinical oncology pipeline. CEO Kevin Lee highlights his invaluable contributions to the company’s ongoing success. Bicycle, known for its innovative Bicycle® technology, is advancing multiple clinical trials, including BT1718 and BT5528, targeting significant unmet medical needs.

Bicycle Therapeutics, a biotechnology company specializing in innovative therapeutics, will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 8:40 a.m. ET. The event will be conducted virtually and will be accessible via a live webcast on Bicycle's website. Additionally, an archived replay will be available for 90 days post-event. Bicycle is known for its proprietary Bicycles technology, with ongoing clinical trials for its lead product candidate, BT1718, and additional candidates BT5528 and BT8009.

Bicycle Therapeutics (NASDAQ: BCYC) reported its fourth-quarter and full-year 2020 financial results, highlighting significant advancements despite COVID-19 challenges. The company has progressed multiple Bicycle Toxin Conjugates (BTCs) and is preparing for the clinical start of its first tumor-targeted immune cell agonist (TICA). Financially, Bicycle ended 2020 with $136 million in cash, up from $92 million in 2019, driven by successful fundraising efforts. However, the company reported a net loss of $51 million for 2020, with increased expenses in research and development and general administration.

Bicycle Therapeutics (NASDAQ:BCYC) announced the publication of preclinical studies on its innovative synthetic tumor-targeted immune cell agonists (TICAs) in the Journal for ImmunoTherapy of Cancer. The research highlights the potential of TICAs to enhance anticancer immunity through the modulation of CD137. Findings demonstrated that TICAs could efficiently co-stimulate human immune cells and eliminate tumors in preclinical models. The company plans to initiate a clinical trial for its lead TICA, BT7480, within the year, showcasing its commitment to advancing cancer immunotherapy.

Bicycle Therapeutics plc (NASDAQ: BCYC) reported notable advancements in its oncology pipeline, emphasizing its next-generation Bicycle Toxin Conjugates (BTCs) and tumor-targeted immune cell agonists (TICAs). Key programs include BT1718, which is in Phase IIa trials showing signs of anti-tumor activity, and BT5528, which has demonstrated preliminary efficacy in the ongoing Phase I trial. The company is also on track to expand its clinical trials for BT8009 and BT7480, with expectations for multiple clinical updates in 2021. Overall, Bicycle is positioning itself for significant milestones ahead.